



Nanomaterials in targeting amyloid- β oligomers: current advances and future directions for Alzheimer's disease diagnosis and therapy

Shiwani Randhawa^{1,2}, Trilok Chand Saini^{1,2}, Manik Bathla^{1,2}, Rahul Bhardwaj^{1,2}, Rubina Dhiman¹ and Amitabha Acharya^{*1,2,§}

Review

[Open Access](#)

Address:

¹Biotechnology Division, C.S.I.R – Institute of Himalayan Bioresource Technology, Palampur, Himachal Pradesh, 176061, India and ²Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh, 201002, India

Email:

Amitabha Acharya* - amitabha@ihbt.res.in

* Corresponding author

§ Email: amitabhachem@gmail.com; Tel (off): +91-1894-233339; Extn. 397; Fax: +91-1894-230433

Keywords:

Alzheimer's disease; amyloid; amyloid- β oligomers; detection; dissociation; nanomaterials

Beilstein J. Nanotechnol. **2025**, *16*, 561–580.

<https://doi.org/10.3762/bjnano.16.44>

Received: 27 November 2024

Accepted: 03 April 2025

Published: 22 April 2025

This article is part of the thematic issue "Advances in nanobiomaterials for neurodegenerative disease management".

Guest Editor: M. Kujawska



© 2025 Randhawa et al.; licensee Beilstein-Institut.
License and terms: see end of document.

Abstract

The amyloid cascade hypothesis posits that amyloid- β oligomers (A β Os) are the most neurotoxic species in Alzheimer's disease (AD). These oligomers, characterized by their high β -sheet content, have been shown to significantly disrupt cell membranes, induce local inflammation, and impair autophagy processes, which collectively contribute to neuronal loss. As such, targeting A β Os specifically, rather than solely focusing on amyloid- β fibrils (A β Fs), may offer a more effective therapeutic approach for AD. Recent advances in detection and diagnosis have emphasized the importance of accurately identifying A β Os in patient samples, enhancing the potential for timely intervention. In recent years, nanomaterials (NMs) have emerged as promising agents for addressing A β Os regarding their multivalent interactions, which can more effectively detect and inhibit A β O formation. This review provides an in-depth analysis of various nanochaperones developed to target A β Os, detailing their mechanisms of action and therapeutic potential via focusing on two main strategies, namely, disruption of A β Os through direct interaction and the inhibition of A β O nucleation by binding to intermediates of the oligomerization process. Evidence from in vivo studies indicate that NMs hold promise for ameliorating AD symptoms. Additionally, the review explores the different interaction mechanisms through which nanoparticles exhibit their inhibitory effects on A β Os, providing insights into their potential for clinical application. This comprehensive overview highlights the current advancements in NM-based therapies for AD and outlines future research directions aimed at optimizing these innovative treatments.

Review


Introduction

The etiology of Alzheimer's disease (AD) has traditionally been linked to the presence of amyloid- β 42 (A β 42), a protein widely recognized as a key marker of the disease. However, a growing body of recent scientific evidence suggests that it may be the amyloid oligomers with smaller molecular weight, rather than the more conspicuous amyloid fibrils, that play a pivotal role in the development and progression of various protein misfolding diseases, including neurodegenerative disorders and type-II diabetes. Numerous studies have highlighted a disconnect between the accumulation of amyloid plaques observed in post-mortem examinations and the neurological deficits experienced by patients during their lives. To explain this lack of correlation, multiple hypotheses have been proposed. Among these, the "oligomer hypothesis" has recently emerged as a leading explanation, positing that the toxic effects of these small oligomers may be more critical to the pathology of AD than the larger aggregated plaques. This shift in focus highlights the need for a deeper understanding of how these oligomers contribute to the disease process [1,2]. The proposition regarding amyloid oligomers has garnered significant attention over time, primarily because of three key observations related to drug candidates for AD therapy. These observations are (i) ineffectiveness of plaque-targeting therapies, that is, therapeutic agents that focus solely on the removal of amyloid plaques or amyloid fibrils have not demonstrated substantial improvements in patients' cognitive behaviors; (ii) efficacy of oligomer-targeting drugs, that is, drug candidates that specifically target amyloid- β oligomers (A β Os) have shown greater clinical effectiveness in treating AD patients; and (iii) influence of the APOE4 allele, that is, positive clinical trial outcomes tend to have a higher concentration of A β Os in the brain of individuals carrying the E4 allele of apolipoprotein E (APOE4). The origins of A β Os in AD patients remain a subject of debate and require further extensive research for a definitive understanding. Genetic studies on AD patients indicate that mutations in the amyloid precursor protein (APP), such as the Osaka [3] and Arctic mutations [4], lead to an overproduction of soluble A β Os. These mutations are associated with an earlier onset of AD, often occurring before the age of 50 [5], suggesting that certain genetic factors can significantly accelerate the development of the disease. In contrast, the Icelandic mutations appear to have a protective effect, reducing both the overall levels of A β Os and the concentrations of amyloid fibrils, which are another form of amyloid aggregation linked to AD [6]. Additionally, the presence of the APOE4 genotype is notable, as it is found in approximately 65% of AD patients [5]. This genotype is associated with an increased tendency for amyloid monomers to aggregate into A β Os, potentially contributing to the pathology of the disease [7]. Comparisons between AD patients who carry the APOE4 allele and

those who do not reveal that the former group has about three times the concentration of A β Os in the brain. This suggests that the APOE4 genotype plays a significant role in the progression of AD by facilitating the accumulation of these toxic oligomers [8]. A β Os exhibit several distinct characteristics that set them apart from amyloid- β fibrils (A β Fs). They are small, globular aggregates that display a metastable and transient nature, along with a higher content of β -sheet structures [9]. These small protein aggregates can arise from specific interactions between *n*-mers (oligomers formed from a defined number of monomers), or from non-specific interactions, akin to micelles. The precise mechanisms underlying the formation of A β Os during the growth of A β Fs remain elusive. However, researchers have identified three main pathways to explain this process, as illustrated in Figure 1. The first two pathways fall under the "on-pathway" model, which includes nucleated polymerization and nucleated conformational conversion. These models suggest that oligomers are transient species that form as intermediates during the transition from monomers to mature A β Fs. In this context, A β Os are considered stepping stones on the pathway to fibril formation. In contrast, the third model, known as the "off-pathway" formation of A β Os, asserts that oligomers represent a separate class of aggregates that do not progress to form fibrils. This model highlights the possibility that A β Os may have distinct properties and biological implications that differ from those of amyloid fibrils, suggesting a more complex relationship in the pathology of amyloid-related diseases. Understanding these pathways is crucial for unraveling the role of A β Os in the development and progression of AD [10].

Numerous studies have indicated a strong association between neuronal dysfunction and the presence of oligomeric species. Researchers are increasingly coming to a consensus that the neurotoxicity observed in neurodegenerative diseases (NDs) is not attributable to a single, isolated toxic conformer of amyloid oligomers. Instead, it appears to be the result of a diverse and heterogeneous population of oligomers. Understanding the factors that influence their toxic nature is crucial for developing tools for early detection and treatment. Despite years of research, targeting A β Os has yielded limited clinical success, primarily because of the tendency to treat patients at later stages, when extensive brain damage has already occurred. However, monoclonal antibodies targeting A β Os such as aducanumab, have demonstrated promising efficacy, leading to its FDA approval [12].

Early diagnosis of AD by targeting A β Os is crucial for improving outcomes. Current imaging methods, such as computed tomography (CT)/positron emission tomography (PET) with



FDA-approved ^{18}F -radiotracers (e.g., Amyvid[™] and Tauvid[™]), detect plaques and tau tangles but not A β Os [13]. There is an urgent need for agents targeting A β Os to enable earlier and more accurate diagnosis and treatment. Despite extensive research, most AD treatments only offer temporary symptom relief and fail to target the root causes of the disease. This limited effectiveness stems from AD's complex and multifactorial nature, which complicates early detection and the identification of reliable biomarkers and therapeutic targets. Moreover, the blood–brain barrier (BBB) poses a significant obstacle to effective drug delivery, further hindering the development of successful treatments.

Nanomaterials (NMs) offer promising solutions for the early detection and treatment of A β Os in AD. Because of their nanoscale size, NMs can interact with biological systems in ways that traditional treatments cannot. Their unique properties such as high surface area, quantum effects, and specific physicochemical traits make them ideal for developing advanced biosensors for early diagnosis and improving the sensitivity of A β O detection. In imaging, nanoparticles (NPs) can help to visualize localized protein accumulation, complementing existing diagnostic methods. Materials such as carbon-based NMs (e.g., graphene oxide) and metal NPs (e.g., gold and

silver) enhance imaging sensitivity because of their distinct electrical or photoluminescent properties. For treatment, NPs can serve as drug carriers, improving delivery across the BBB and reducing side effects. Their large surface area allows for controlled drug release and targeted therapy, enhancing treatment efficacy. Additionally, NMs can interact directly with tissues and cells, potentially halting disease progression by preventing protein misfolding and the formation of toxic oligomers, a hallmark of AD pathology. Overall, nanotechnology holds significant potential to advance both the diagnosis and treatment of A β O-driven AD [14], and we will discuss these topics in the following.

Mechanisms of neuronal cell toxicity induced by A β Os

Research has shown that A β Os possess a remarkable ability to penetrate cell membranes, largely due to their capacity to form porins within the lipid bilayer. This ability arises from the increased presence of β -sheet structures in A β Os, which can create distinct rafts in the membrane. These ring-shaped oligomers adhere to the cell membrane and inflict damage either by directly penetrating the membrane or by aggregating into fibrils that disrupt cellular integrity. Once internalized, A β Os activate *N*-methyl-D-aspartate-type glutamate receptors

(NMDARs) located on neuronal membranes. This activation triggers endoplasmic reticulum (ER) stress through the stimulation of phospholipase C, leading to an influx of calcium ions (Ca^{2+}) into the cytosol [15]. Elevated Ca^{2+} levels result in the accumulation of reactive oxygen species (ROS) and reactive nitrogen species, contributing to oxidative stress within the cell [16]. The increase in cytosolic Ca^{2+} also promotes the phosphorylation of ATP proteins, which, in turn, leads to the enhanced production of A β 42 and A β Os, creating a vicious cycle. This cascade ultimately results in further spikes in intracellular Ca^{2+} concentrations sourced from the ER, which is linked to memory impairments commonly associated with AD. Additionally, elevated cytosolic Ca^{2+} activates the enzyme calcineurin, which is implicated in the activation of the Bcl-2-associated death promoter (BAD). This process, coupled with oxidative stress pathways originating from mitochondrial dysfunction, facilitates the release of cytochrome c from the mitochondria. This release is a key event that promotes caspase activation, initiating pro-apoptotic signaling that drives neuronal apoptosis [17]. Furthermore, A β Os can disrupt the membranes of endosomes and lysosomes, exacerbating neuronal cell death [18].

In another dimension, A β Os exhibit a strong affinity for cellular prion protein (PrPC) receptors, binding to them irreversibly. The formation of the oligomer–PrPC complex, together with the co-activation of the mGluR5 receptor, leads to the activation of

intracellular Fyn kinase. This activation causes dysregulation of calcium ion homeostasis, hyperphosphorylation of tau protein, and disruption of synaptic functions. Together, these processes, as depicted in Figure 2, contribute significantly to the neurodegenerative pathways associated with AD, highlighting the multifaceted role of A β Os in neuronal dysfunction and cell death [19].

Conventional methods for addressing the presence and toxicity of A β Os

A β Os are small aggregates formed from the misfolding and aggregation of amyloid- β (A β) peptides, primarily A β 40 and A β 42. These oligomers typically consist of a limited number of A β monomers, often ranging from trimers to tetramers, but they can form larger aggregates under certain conditions. Their small size and unique structural properties contribute to several challenges in therapeutic targeting. They are considerably smaller than fibrillar aggregates and plaques, making them difficult to target with conventional binding agents. A β Os exhibit significant heterogeneity in size and conformation. This variability means that a single therapeutic agent may not effectively recognize all oligomeric forms, complicating the development of broad-spectrum therapies. Unlike larger aggregates, which may present multiple binding sites, A β Os have fewer defined surface characteristics that can be targeted. A β Os can interconvert between different oligomeric states and may also exist in equi-




Figure 2: Illustration of calcium-mediated toxicity induced by oligomers. Oligomers initiate a calcium cascade that results in a series of harmful effects on cellular health. Elevated intracellular calcium levels activate phospholipase C (PLC), triggering endoplasmic reticulum (ER) stress and additional calcium release. This positive feedback loop exacerbates calcium dysregulation, leading to increased amyloid- β formation, oxidative stress, mitochondrial dysfunction, and ultimately apoptosis. (Figure 2 was created using Microsoft PowerPoint and Servier Medical Art (<https://smart.servier.com>)).

librium with monomeric and fibrillar forms. This dynamic nature poses a challenge for therapies that rely on specific binding, as the target may change rapidly in response to environmental factors or therapeutic intervention. As a result, the predominant strategies for targeting A β Os have largely been confined to biologics, particularly monoclonal and polyclonal antibodies. The advantages of using antibodies stem from their remarkable capacity to recognize conformational epitopes that are unique to various oligomeric forms, thereby facilitating the selective targeting of pathogenic A β Os.

The most widely utilized monoclonal antibodies in AD research are 6E10 and 4G8 [19–21]. These antibodies were generated by immunizing mice with specific peptide fragments of A β , allowing them to bind effectively to amyloid aggregates. Importantly, the development of “conformation-dependent” antibodies, such as A11 and OC, marked a significant advancement in the field, as they were among the first to differentiate between A β Os and A β Fs. This distinction is crucial for understanding the pathophysiology of AD, as oligomers are believed to be more toxic than fibrils [22–24].

In addition, the polyclonal antibody M94 has demonstrated high selectivity towards pathogenic A β Os, while not recognizing physiological A β monomers. This selectivity is vital, as it helps to minimize potential off-target effects and enhances the therapeutic profile of the antibodies [25]. Additionally, the monoclonal antibody mAb158 selectively targets soluble A β Os, including protofibrils, rather than monomeric A β or APP, highlighting its specific ability to focus on oligomers [26–28]. Recent developments have introduced novel approaches to target A β Os, such as the work by Haynes et al., who reported the creation of a unique anti-soluble A β O (E3) nanobody derived from an alpaca immunized with soluble A β Os. This E3 nanobody, conjugated with carboxyfluorescein (FAM), demonstrated effective recognition of both soluble A β Os and A β plaques, highlighting the potential for nanobody technology to complement traditional antibody approaches [29]. Conventional methods for targeting A β Os primarily rely on the use of antibodies because of their ability to recognize specific conformational epitopes associated with oligomers. The development of monoclonal and polyclonal antibodies has significantly advanced our understanding of A β Os in AD, allowing for targeted therapeutic and diagnostic strategies. While traditional antibody-based approaches remain valuable, ongoing innovations, such as the development of nanobodies and nanochaperones, promise to enhance the specificity and efficacy of oligomer targeting. Ongoing research into traditional therapeutic approaches, such as small molecules/compounds, immunotherapy, peptidomimetics, and chaperon proteins, as outlined in Table 1, continues to be a critical part of the effort to tackle AD. These

conventional strategies, which target different aspects of A β O formation and accumulation, have shown promise in managing AD pathology. However, they face significant challenges, including limited efficacy and specificity in targeting the diverse forms of A β Os. By combining the strengths of both established and new technologies, researchers aim to develop more effective therapies for AD that can specifically target A β Os and ultimately slow or halt the progression of the disease.

Emerging therapeutic approaches in clinical trials for targeting A β Os

Recent advancements have positioned immunotherapeutic approaches utilizing anti-A β antibodies as some of the most promising strategies for the treatment of AD. Notably, the first generation of anti-A β antibody therapies, including aducanumab, lecanemab, and donanemab, has demonstrated significant therapeutic potential in combating AD. Aducanumab and lecanemab have already received FDA approval, while donanemab is currently undergoing clinical evaluation [49]. In a noteworthy study by Sandberg et al., an oligomer-specific antibody known as ALZ 201 was reported to effectively mitigate the toxic effects associated with extracts from AD brains. This research confirmed that ALZ 201 selectively recognizes A β Os and, interestingly, demonstrated efficacy in protecting neurons exposed to AD brain extract. ALZ 201 is presently in preclinical development, highlighting its potential as a therapeutic candidate [50]. Lecanemab, another anti-A β antibody, has been found to exhibit a higher affinity for A β protofibrils characterized as “beaded” curvilinear fibrils and recognized as a specific form of A β Os than other known antibodies such as aducanumab or gantenerumab. Furthermore, clinical observations have indicated that treatment with lecanemab is associated with a reduction in cognitive decline, underscoring its promise as a viable therapeutic option in the fight against AD [49].

The landscape of AD treatment is evolving, with emerging therapeutic approaches in clinical trials targeting A β Os offering new hope for patients. Monoclonal antibodies and oligomer-specific antibodies are at the forefront of this research. As clinical trials progress, these therapies hold the potential to significantly improve cognitive outcomes and quality of life for individuals affected by AD, underscoring the importance of targeted interventions in combating this complex neurodegenerative disorder. Conventional approaches have shown promise in the detection and treatment of A β Os in AD. However, NP-based approaches present a complementary and potentially more versatile strategy for addressing A β Os in AD. In our review, we discuss a range of strategies aimed at targeting A β Os, and these approaches are illustrated in Figure 3. Figure 3 provides an overview of the different therapeutic strategies, highlighting both conventional and emerging

Table 1: Classification of therapeutic strategies targeting A β O and their mechanisms of action.

Class	Compound	Target	Mechanism of action	Reference
immunotherapy	aducanumab	A β O and A β Fs	aducanumab interacts with the area covering residues 3–7 in the N-terminal region of A β	[30]
	crenezumab	A β aggregates (including A β O)	crenezumab, a fully humanized IgG4 monoclonal antibody, reduces the activation of Fc-gamma receptors (Fc γ Rs) while preserving Fc γ R-mediated microglial phagocytosis and facilitating the clearance of A β O	[31]
	gantenerumab	A β O, plaque, and A β Fs	mechanism of action involves binding with high affinity to both the N-terminal and central regions of A β peptides	[32]
	bapineuzumab	soluble A β O and A β Fs	changes in APOE4 carrier expression	[33]
	PMN310	A β O	humanized PMN310 inhibits A β O-induced memory impairment and diminished synaptic loss and inflammation	[34]
small molecule/compounds	curcumin	A β O, plaque, and A β Fs	curcumin directly interacts with small amyloid species to inhibit aggregation and fibril production both in vitro and in vivo	[35]
	epigallocatechin gallate (EGCG)	A β O and A β Fs	the interactions of EGCG are determined by hydrophobic π – π and hydrophilic interactions with the aromatic side chains and A β backbone, respectively	[36]
	melatonin	A β O	melatonin treatment inhibits the A β 1–42-induced decline in Notch1, NTMF, and NICD both in vivo and in vitro	[37]
	trodusquemine	A β O	selectively binds to oligomeric species and reduces the toxicity	[38]
	methylene blue	A β O	inhibits the oligomer formation by selectively inducing the fibril formation	[39]
	sulforaphane	A β O	decreases oligomer production, tau phosphorylation, oxidative stress, and inflammation, while enhancing cognition in PS1V97L Tg mice	[40]
	transthyretin (TTR)	A β O	TTR tetramers inhibit A β aggregation in vitro through an interaction between the thyroxine binding pocket of the TTR tetramer and A β residues 18–21	[41]
peptidomimetic	RI-OR2	A β O and A β Fs	attaches itself to its corresponding region (KLVFF, residues 16–20) in native A β and disrupt A β self-association	[42]
	LPFFD	A β plaque and A β Fs	the absence of a proton on the secondary substituted nitrogen in the peptide bond of the proline residue may impede the development of intramolecular hydrogen bonds inside fibrils	[43]
	D3	A β O	D3 derivative peptides bind to A β in monomeric stage and stabilize these species within the diverse equilibria of A β assemblies, ultimately resulting in the eradication of A β O	[44]
	APPI	A β plaque and A β Fs	the binding of this 20-mer cyclic peptide to A β 42 (in a 1:1 molar ratio) promotes the development of A β 42 aggregates, thereby ameliorating A β 42-mediated cellular toxicity	[45]

Table 1: Classification of therapeutic strategies targeting AβOs and their mechanisms of action. (continued)

chaperon proteins	BRICHOS domain	Aβ plaque, AβOs, and AβFs	interferes with Aβ in the nucleation process and extends the lag phase	[46]
	HSP104	AβOs, protofibrils, and AβFs	the inhibition of Aβ fibrillization by Hsp104 is evident at Hsp104/Aβ, indicating a selective involvement of Hsp104 with aggregation intermediates (such as oligomers and protofibrils), during amyloid formation	[47]
	αB-crystallin	AβOs	αB-crystallin interacts with the monomer and oligomeric state of the proteins via capping the β-sheet elongation surfaces; it restricts the nucleation phase, which in turn does not allow the oligomer to form fibrils	[48]




Figure 3: This figure summarizes the key strategies discussed in our review for targeting AβOs in AD. Aβ monomers, generated from APP through β-secretase activity, aggregate to form oligomers and subsequently amyloid plaques. The diagram highlights various therapeutic approaches, such as immunotherapy and antibody-conjugated NPs designed to enhance microglial phagocytosis for Aβ clearance, as well as NP-based techniques aimed at disrupting Aβ aggregates and preventing their toxic effects. (Figure 3 was created using ChemDraw Professional (Version 20.1.1.125) and Servier Medical Art (<https://smart.servier.com>)).

methods for addressing the challenges posed by A β Os in AD pathology.

Nanoparticle-based approaches for the diagnosis and dissociation/inhibition of A β Os

Although conventional approaches for diagnosing and targeting A β Os have laid the foundation for AD treatment, they often face limitations. For example, monoclonal antibodies, while capable of binding A β Os, may also interact with other forms of A β , including fibrils or monomers, leading to off-target effects and reduced efficacy. Recent advancements in nanotechnology offer a promising alternative with NPs specifically designed for AD diagnosis and A β O inhibition. These NPs possess unique properties, including variable size and shape and readily modifiable surfaces. These features allow for targeted and effective therapeutic strategies. In this section, we discuss NPs specifically designed for the diagnosis and inhibition of A β Os.

One example of this innovative approach is demonstrated by Viola et al., who designed mono-dispersed nitro-dopamine (nDOPA)- and polyethylene glycol (PEG)-stabilized magnetic nanostructures (MNSs) in a size range of 12–16 nm. The surface of these MNSs was further modified with oligomer-specific antibodies, creating a stable nanobioconjugate for both in vitro and in vivo applications. The MNSs could detect toxic A β Os present on nerve cell surfaces in vitro, demonstrating their specificity and effectiveness. Additionally, upon intranasal delivery in a mouse model, these MNSs rapidly targeted A β Os under in vivo conditions, providing strong MRI contrast, thus supporting their potential for non-invasive diagnostic imaging of early-stage AD [51]. In another study, a similar approach was utilized by Wang et al.; they developed a A β O-targeting gadolinium-based NIR/MR dual-modal theranostic nanoprobe. The developed nanoprobe was used as an efficient and sensitive MR/NIR contrasting agent for the detection of A β Os in different age groups of transgenic AD mice. The theranostic nanoprobe also showed strong inhibitory effect against A β fibrillation and improved associated neurotoxicity [52]. Shifting from imaging to electrochemical approaches, researchers have developed biosensors comprising immobilized thiolated PrPC peptides on a graphene oxide/gold nanoparticle hydrogel electrode. This nanobiosensor displayed high specificity and sensitivity for detecting soluble A β Os in artificial cerebrospinal fluid (CSF) or blood plasma. It was capable of effectively distinguishing A β Os from A β monomers and fibrils, indicating its utility for accurate and selective detection of A β Os [53]. Another group of researchers utilized a similar approach of electrochemical detection of A β Os via a nanobiosensor consisting of gold nanoparticles (AuNPs) embedded in a conductive polymeric matrix. For this, the surface of the AuNPs was further modified with PrPC, which acted as the biorecognition

element for the specific detection of A β Os in ex vivo real samples, viz., CSF and blood tests [54]. Researchers have also employed the surface plasmon resonance (SPR) of citric acid-coated AuNPs, to specifically detect and quantify A β 40 oligomers, as the SPR absorption band of AuNPs was found to be sensitive to the presence of A β Os [55]. While exploring the range of A β O detection methods, Liu et al. developed a fluorescence-based system using a FAM-labeled DNA aptamer fluorophore along with a nanoquencher attached to self-assembled polydopamine nanospheres. This nanosystem showed selective recognition of A β Os through a “fluorescence-signal on” mechanism, where the FAM-DNA aptamer interacted with A β Os, causing a hairpin-like conformational change that triggered a fluorescent signal. This approach combined sensitivity with specificity, providing a promising tool for the detection of A β Os [56]. While the aforementioned NP-based systems excel in identifying and imaging A β Os, these technologies also pave the way for developing therapeutic strategies aimed at inhibiting the formation of toxic A β Os. Liu et al. synthesized multifunctional superparamagnetic iron oxide nanoparticles (SPIONs) conjugated with a specific scFv antibody (W20) targeting A β Os and a class-A scavenger receptor activator (XD4). These W20/XD4-SPIONs demonstrated promising results in mitigating the cytotoxicity induced by A β Os and enhancing microglial phagocytosis of these toxic aggregates [57]. Previously, the same NPs were found to show promising early diagnostic potential for AD [58]. Brambilla et al. employed a combination of experimental and computational approaches to investigate the interaction between PEGylated NPs and A β monomers. Their findings revealed that surface interactions between NPs and A β monomers effectively inhibited the formation of A β Os [59]. Building upon their previous research, Parikh et al. developed a curcumin-loaded self-nanomicellizing solid dispersion system (Cur-SNSDS) to significantly enhance the in vivo bioavailability of curcumin. This novel NP system demonstrated superior safety and efficacy in mitigating A β 42 oligomer-induced toxicity in SH-SY5Y695 APP human neuroblastoma cells compared to pure curcumin. Moreover, the Cur-SNSDS system effectively prevented cognitive decline in aged APPSwe/PS1deE9 mice, suggesting its potential as a therapeutic intervention for AD [60]. Ultimately, these diverse examples illustrate the transformative, versatile, and effective approach of NP-based strategies for the detection and inhibition of A β Os (Table 2). Their ability to target and interact with A β Os presents a highly promising avenue for future therapeutic development. As research continues in this area, NPs show promising potential to revolutionize how we diagnose and manage NDs such as Alzheimer’s.

In this review, we systematically categorize NPs used for the diagnosis and inhibition of A β Os based on their composition

Table 2: NP-based strategies for diagnosing and inhibiting A β O formation, as well as mitigating the associated toxicity.

Nanoparticles	Conjugation/modification	Mechanism of action	Reference
poly(dopamine) nanospheres	conjugated with carboxyfluorescein-labeled DNA aptamer	detection of A β O with high sensitivity using carboxyfluorescein-labeled DNA aptamer–polydopamine nanospheres, capable of identifying concentrations as low as 20 nM	[56]
gold nanoparticles	casein-coated gold nanoparticles	chaperones together with gold nanoparticles effectively neutralized A β aggregates, reducing their toxic effects	[61]
iron oxide nanoparticles	conjugated with A β oligomer-specific scFv antibody W20 and class-A scavenger receptor activator XD4	mitigation of A β O-induced cell toxicity and stimulate microglial phagocytosis of A β	[57]
single-wall carbon nanotubes (SWCNTs)	hydroxylated SWCNTs	disruption of the beta-sheet conformation of A β 16–22 oligomers, leading to the formation of less structured, disordered aggregates	[62]
PLGA NPs	—	interaction with A β O during the elongation phase via π – π and hydrophobic interactions, destabilizing their harmful structure	[63]
gold nanoparticles	conjugated with oligomer specific antibody	detection of A β 1–40 with exceptional sensitivity, capable of identifying concentrations as low as 1 fg/mL	[64]
PLGA NPs	conjugated with 83-14 mAb and encapsulated with rosmarinic acid (RA) and curcumin (CUR)	enhanced cellular uptake of RA and CUR when delivered using these nanocarriers, indicating that the antibody is crucial for improving nanoparticle delivery to the brain	[65]
exosomes (EXOs)	M2 microglia-derived exosomes	M2-EXOs were found to decrease A β plaque formation and A β oligomer expression in AD cell models, suggesting a protective role in AD pathogenesis through the enhancement of PINK1/Parkin-mediated mitophagy	[66]
AuNPs	conjugated with chiral L- and D-glutathione	D-enantiomer showed a stronger binding affinity to A β 42 and demonstrated improved reversal of behavioral deficits in mice modeling Alzheimer's disease	[67]
AuNPs	conjugated with glucosamine	the abundance of carbohydrate groups on the nanoparticle surface formed robust hydrogen bonds with protein oligomers, preventing their aggregation	[68]
PLGA NPs	conjugated with PEG and encapsulated with indirubin-3'-monoxime (I3M)	nanoparticles continuously released I3M, improving the ability to inhibit A β aggregation; additionally, PLGA-PEG nanoparticles enhanced the uptake of I3M by PC12 cells, demonstrating their potential to protect neurons from A β O	[69]

and functionalization. This bifurcation allows for a clearer understanding of the diverse mechanisms and applications of NPs in addressing AD. We have organized the NPs into four primary categories, namely, carbon based nanomaterials (CNMs), metal based NMs, biomimetic NMs and antibody-functionalized NMs.

Carbon-based nanomaterials for the detection and inhibition of A β O

Recent advances in nanomedicine have spotlighted CNMs because of their remarkable physicochemical properties, diverse structural forms, and potential applications in combating NDs. The unique characteristics of CNMs, including their hydrophobic surfaces and variable dimensions, enable them to interact effectively with biomolecules, making them valuable tools in biomedical research and therapeutic applications. CNMs can be categorized into three primary forms, namely, zero-dimensional fullerenes (e.g., C₆₀), one-dimensional car-

bon nanotubes (CNTs), and two-dimensional graphene. Each of these NMs possesses distinct attributes that facilitate their engagement with proteins and peptides, particularly those associated with NDs like AD. Research has demonstrated the ability of fullerenes to prevent the aggregation of A β peptides. For instance, molecular dynamics simulations have shown that fullerenes inhibit the fibrillation of the hydrophobic KLVFFAE peptide by disrupting the formation of β -sheet oligomers. This property is particularly significant as β -sheet formation is a critical step in the aggregation pathway leading to neurotoxic amyloid fibrils [70]. Further investigations revealed that fullerene C₆₀ interacts strongly with non-polar aliphatic groups in polar residues of the GNNQQNY peptide, effectively redirecting the formation of potentially toxic oligomers towards disordered coil structures. This mechanism not only hinders fibril formation but also shifts the balance toward less harmful aggregates [71]. Single-walled carbon nanotubes (SWCNTs) have emerged as another promising CNM for the detection and

inhibition of A β Os. Studies indicate that hydroxylated SWCNTs significantly inhibit the β -sheet formation of A β peptides [17–23]. By facilitating the formation of disordered aggregates, these nanomaterials diminish the aggregation propensity of A β peptides, thereby mitigating their neurotoxic effects [62,72]. In addition to their inhibitory capabilities, SWCNTs can serve as effective sensors for A β Os. Their ability to interfere with β -sheet formation, a hallmark of A β aggregation, has been confirmed through comprehensive molecular dynamics simulations. These studies reveal that SWCNTs interact with the hydrophobic residues of A β peptides, particularly through π -stacking interactions with aromatic amino acids such as phenylalanine. This interaction destabilizes the prefibrillar β -sheet structures, preventing the formation of toxic oligomers and promoting the aggregation of less harmful conformations [73]. Moreover, the development of positively charged carbon quantum dots has shown promise in preventing the aggregation of amyloid proteins, specifically by inhibiting the formation of hetero-oligomers between islet amyloid polypeptide (IAPP) and A β 42. Such findings highlight the versatility of CNMs in addressing different aspects of amyloid aggregation [74]. In summary, CNMs present a multifaceted approach to the detection and inhibition of A β Os. Their unique structural properties and interactions with amyloid peptides hold significant potential for the development of innovative therapeutic strategies aimed at combating NDs. As research in this field continues to advance, the integration of CNMs into clinical applications may offer new avenues for early detection and intervention in AD and related disorders.

Metal nanomaterials for detection and inhibition of A β Os

Metal NPs have emerged as pivotal tools in the detection and inhibition of A β 1–42 oligomers. Their unique optical and electrical properties, particularly those of gold and silver NPs, enhance sensitivity and specificity in identifying the early stages of A β aggregation. By binding to A β Os, these NPs facilitate label-free detection methods such as SPR, colorimetric changes, and fluorescence amplification, enabling straightforward real-time monitoring of oligomer formation. This innovative approach not only deepens our understanding of amyloid pathology but also contributes to the development of diagnostic strategies for NDs. Zhou and colleagues introduced an advanced electrochemical aptasensor that utilizes metal-organic frameworks (MOFs) as signal probes for detecting A β Os. They engineered an electrode modified with gold nanoflowers to capture targets, employing aptamer-tagged gold nanoparticle/Cu-MOFs conjugates to produce sensitive signals. This resulted in a highly effective sandwich sensor capable of detecting A β Os in a linear range from 1 nM to 2 μ M, demonstrating a correlation coefficient of 0.996 and a low detection limit of 0.45 nM

[75]. Phan and team developed a robust and straightforward method for creating multichamber paper devices using wax printing techniques, which they applied to detect A β Os. This approach leverages copper-enhanced gold nanoprobe colorimetric immunoblotting, achieving detection limits as low as 23.7 pg/mL, visible through a smartphone camera, and up to 320 pg/mL with the naked eye [76]. Zhao and collaborators utilized AuNPs embedded in various matrices to construct three-dimensional layers for detecting A β Os. Among their innovations, PrPC/AuNPs embedded in a Ppy-3-COOH matrix (AuNPs-E-Ppy-3-COOH) exhibited superior sensitivity, with a detection range spanning from 10^{-9} to 10^3 nM [77]. An electrochemical, label-free aptassay developed by Gallo-Orive et al. incorporates graphene oxide–gold nanoparticles/nickel/platinum nanoparticles for the rapid and accurate detection of A β Os in complex clinical samples, such as brain tissue and CSF from Alzheimer's patients. This method showcased exceptional sensitivity with a limit of detection of 0.10 pg/mL, demonstrating reproducibility and rapidity [78].

Metallic NPs have gained considerable attention as potential therapeutic agents regarding A β O formation. Their unique surface characteristics enable specific interactions with amyloid fibrils, effectively inhibiting oligomerization and reducing neuronal cell death. Moreover, these NPs can be functionalized with targeted ligands, enhancing their selectivity and efficacy in therapeutic applications aimed at A β -induced neurotoxicity. Recent research has focused on cyclometallated palladium complexes (Pd-1, Pd-2, and Pd-3), which incorporate anthracene and pyrene within a tridentate ligand framework. These complexes specifically target the oligomerization of soluble A β 1–42 peptides. Among them, Pd-3 has shown significant promise, exhibiting the greatest reduction in A β 1–42 peptide-induced cytotoxicity in Neuro-2a cell lines. Structural studies indicate that these palladium complexes interact with both the fibrillar (PDB: 2BEG) and monomeric (PDB: 1IYT) forms of the A β 1–42 peptide. This interaction occurs through a variety of binding modalities, including hydrophobic and hydrogen bonding, leading to substantial inhibition of peptide aggregation [79]. In another innovative approach, Javed et al. evaluated the inhibitory potential of casein-coated AuNPs against oligomers through molecular dynamics simulations. Their findings demonstrated that these NPs effectively bind to oligomeric species, preventing the formation of fibrillar structures [61]. The influence of varying diameters and lengths of cetyltrimethylammonium bromide-stabilized gold nanorods (AuNRs) on A β oligomerization and fibrillation has also been thoroughly investigated. Fluorescence studies revealed that the presence of the AuNRs significantly inhibits the development of larger oligomers and fibrils, with inhibition efficacy diminishing as the diameter of the NPs decreases [80]. In a different

approach, Randhawa et al. designed glucosamine-conjugated gold nanoparticles (Gln@CA-AuNP), which demonstrated strong inhibition of hen egg-white lysozyme oligomers (HEWL_O) in comparison to fibrils (HEWL_F) (Figure 4). The high density of carbohydrate moieties on the NP surface facilitated strong hydrogen bonding with protein oligomers,

preventing their aggregation. Additionally, Gln@CA-AuNP was found to enhance the production of sulfated glycosaminoglycans, bolster extracellular matrix generation, and confer neuroprotection against oligomeric protein aggregates [68]. These findings collectively underscore the potential of metal-based NPs in not only inhibiting A β oligomerization but also




Figure 4: This figure compares the inhibitory effects of Gln@CA-AuNP on HEWL_O and HEWL_F aggregation demonstrating effective inhibition and potential disruption of oligomer formation. (a) Thioflavin T (ThT) assay, (b) 8-anilino-1-naphthalene-1-sulfonic acid (ANS) fluorescence, (c) circular dichroism spectra, (d) β -sheet content, (e) FTIR, (f) MALDI-TOF, and (g) dot blot with A11 antibody. TEM images (h) HEWL_O and (i) HEWL_F show reduced aggregation after Gln@CA-AuNP treatment. Gln@CA-AuNP inhibits HEWL_O aggregation more effectively than that of HEWL_F. (Figure 4 was reprinted from [68], Nano Today, vol. 56, by S. Randhawa; A. I. Dar; T. C. Saini; M. Bathla; A. Acharya, "Glucosamine conjugated gold nanoparticles modulate protein aggregation induced autophagic neuronal cell death via regulation of intracellular Parkin homeostasis", article no. 102243, Copyright (2024), with permission from Elsevier. This content is not subject to CC BY 4.0).

in paving the way for effective therapeutic strategies against NDs.

Biomimetic nanomaterials based on cell primitives for targeting A β O

The treatment of AD using conventional pharmacological agents has encountered significant challenges, prompting researchers to explore multifunctional nanobiomaterials derived from cell primitives as a promising therapeutic strategy. These biomimetic nanomaterials, comprising components such as cells, extracellular vesicles (EVs), and cell membranes offer several advantages. Their nanoparticulate size facilitates long-term circulation, reduces immune response, enables targeted delivery to lesion sites, and retains distinct biological functions. Emerging studies have highlighted the role of exosomes derived from AD brain samples, which contain elevated levels of A β O. These exosomes are implicated in the propagation of A β O between neurons, suggesting their potential utility as diagnostic biomarkers for early AD detection [81,82]. Researchers are exploring the potential of exosomes as diagnostic tools, leveraging their ability to carry these pathological proteins. Exosomes hold significant diagnostic potential because of their

nanoscale size and the distinct profile of biomolecules they carry, which reflect the characteristics of their parent cells. These biomolecules, including proteins, nucleic acids, and lipids, serve as a “fingerprint” of the originating cells. When cellular conditions change, such as during disease progression, alterations in the composition of exosomes can provide valuable insights into the underlying pathology, making them a promising tool for diagnostic applications. Figure 5 demonstrates how exosomes can transport A β O and tau protein, both of which are key biomarkers associated with AD. The accumulation of these proteins is central to the pathophysiology of AD, and their presence in exosomes can aid in the diagnosis of the disease. By analyzing the presence and levels of A β O and tau protein in exosomes derived from biological fluids, such as blood or CSF, it may be possible to develop non-invasive diagnostic methods for the early detection of AD [83]. However, recent research has begun to investigate the therapeutic potential of exosomes themselves in mitigating A β O-induced toxicity. For instance, Bodart-Santos et al. isolated and characterized EVs from human Wharton’s jelly mesenchymal stem cells (hMSC-EVs) and assessed their neuroprotective effects in primary hippocampal cultures exposed to A β O. Their results indi-




Figure 5: Illustration of the role of exosomes in transporting A β O and tau protein, which are implicated in the accumulation associated with AD. This highlights the potential of exploiting exosomes for diagnostic purposes in detecting these pathological markers. (Figure 5 was reproduced from [83] (© 2021 Hagar M. Soliman et al., published by MDPI, distributed under the terms of the Creative Commons Attribution 4.0 International License, <https://creativecommons.org/licenses/by/4.0/>)).

cated that hMSC-EVs could protect neurons from A β O-induced damage, largely attributed to the transfer of enzymatically active catalase contained within the EVs. This approach holds promise for developing cell-free therapeutic strategies for AD [84]. Additionally, Deng et al. explored exosomes isolated from ultrasound-stimulated human astrocytes (US-HA-Exo). Characterization via nanoparticle tracking and proteomic analysis revealed that ultrasound treatment increased exosome release approximately five-fold. These exosomes exhibited rapid internalization in SH-SY5Y cells and co-localized with FITC-conjugated A β O. Furthermore, CCK-8 assays demonstrated that US-HA-Exos could alleviate A β O toxicity in vitro [85]. Li et al. investigated M2 microglia-derived exosomes (M2-EXOs) and their impact on AD progression. They found that treatment with M2-EXOs in AD cell models, such as HT-22- and MAP2-positive neuronal cells, significantly reduced A β plaque deposition and expression of A β O. Their findings suggest that M2-EXOs confer protective effects in AD pathogenesis through the modulation of PINK1/Parkin-mediated mitophagy [66]. Moreover, Yuyama et al. reported that exosomes secreted by neuronal cells inhibit A β oligomerization by enhancing microglia-mediated A β clearance in vitro [86]. In a different approach, Senapati et al. developed a multifunctional liposome-based platform incorporating a novel cyclic peptide (CP-2) that selectively targets toxic A β O. Their studies indicated that CP-2-liposomes effectively disrupt A β aggregation, mitigate A β -mediated toxicity, and improve cognitive and behavioral outcomes in both in vitro and in vivo models. Notably, these liposomes can cross the BBB, suggesting their potential for precise diagnosis and targeted treatment of AD [87]. In conclusion, biomimetic nanomaterials derived from cell primitives show great promise in addressing the complexities of A β O-related toxicity in AD. Continued research into these innovative approaches could pave the way for effective therapeutic interventions and early diagnostic tools in the fight against AD.

Antibody-functionalized nanomaterials for detection and inhibition of A β O

Unmodified NMs often demonstrate limited selectivity and functionality for A β O detection and inhibition, potentially leading to false positives or inadequate therapeutic outcomes. To enhance their efficacy, NMs can be conjugated with specific ligands or molecules. Antibodies, highly specific proteins that bind to unique epitopes on A β O, provide precise targeting, minimizing off-target effects and maximizing therapeutic efficacy. Their high affinity and specificity allow for efficient capture even at low concentrations, crucial in the complex biological environment of the brain. Recent advancements in immunoassay technology have led to the development of ultrasensitive methods for detecting A β -derived diffusible ligands (ADDLs) and A β O. A novel immunoassay, capable of

detecting ADDLs at femtomole levels, has been developed [88]. This assay is instrumental in understanding the formation of oligomers in vivo as it allows for the detection and quantification of these crucial intermediates in the aggregation process. Zhou et al. introduced an antibody–aptamer sandwich assay utilizing gold nanoparticles for sensitive detection of A β O, achieving a low detection limit of 100 pM, which is crucial for early AD diagnosis [89]. A novel SPR-based immunosensor, enhanced with gold NPs and antibodies, was developed for ultrasensitive detection of A β 1–40. The sensor demonstrated a linear response over nine orders of magnitude, with a detection limit of 1 fg/mL. This approach holds promise for early diagnosis and treatment of amyloid-related diseases [64].

Moreover, antibodies can facilitate the uptake of NPs by cells, a crucial step for delivering therapeutic payloads to intracellular targets like amyloid oligomers within neurons. Antibody-coated PEGylated NPs have been shown to break down A β 42 and may successfully minimize neurotoxicity caused by A β fibrils in the brain. Kuo et al. developed novel NPs composed of poly(acrylamide)-cardiolipin (CL)-poly(lactic-co-glycolic) acid (PLGA) and grafted with surface 83-14 monoclonal antibody (MAb). These NPs were designed to deliver rosmarinic acid (RA) and curcumin (CUR) across the BBB and improve the viability of SK-N-MC cells damaged by amyloid deposits. The researchers found that increasing the concentration of 83-14 MAb on the NPs led to a higher permeability of RA and CUR across the BBB. This suggests that the antibody plays a crucial role in improving the uptake of NPs by cells and drug delivery to the brain [65]. Additionally, antibody conjugation can help to reduce the immunogenicity of NPs, enhancing their safety and tolerability. By combining the unique properties of NPs with the specificity and targeting capabilities of antibodies, these conjugates offer a powerful approach to enhance the specificity, sensitivity, and functionality of diagnostic and therapeutic tools for amyloid oligomers. Many immunotherapies targeting amyloid oligomers have led to side effects such as hydrocephalus, inflammation, and amyloid-related imaging abnormalities [90]. These side effects can be attributed to the activation of the complement system by the interaction of amyloid oligomers and antibodies, leading to the release of proinflammatory fragments. Additionally, complement fragments can further activate microglia, exacerbating neuroinflammation [91]. The effector fragment of the antibody plays a crucial role in these side effects. The ScFv antibody W20, which is specific for amyloid oligomers and lacks the effector fragment, can potentially eliminate these adverse effects. Multifunctional SPIONs conjugated with W20 and XD4, a class A scavenger receptor activator not only have diagnostic value but also retain the anti-amyloid properties of W20 and XD4, inhibiting amyloid aggregation, reducing cytotoxicity, and enhancing

microglial phagocytosis. When administered to APP/PS1 mice, these NPs significantly improved cognitive function and reduced neuropathology associated with AD [58]. Carradori et al. investigated the therapeutic efficacy of antibody-functionalized polymer NPs for AD. In an AD-like transgenic mouse model, these NPs demonstrated significant reductions in brain A β O levels and concomitant improvements in memory function. The NPs were designed to interact with A β 1–42 peptides in the bloodstream, promoting their elimination via a “sink effect”. Treatment with anti-A β 1–42-functionalized NPs resulted in a complete reversal of memory deficits, a substantial decrease in soluble A β and oligomer levels within the brain and a marked increase in A β levels in the plasma, indicating enhanced clearance from the body. These findings highlight the potential of antibody-functionalized NPs as a promising therapeutic strategy for AD [92]. While the use of NPs with antibodies shows great potential, challenges remain in ensuring specificity and minimizing potential immunogenic responses in therapeutic applications.

Factors affecting the therapeutic potential of NP-based AD therapeutic agents

The anti-oligomeric efficacy of NPs depends on their size, shape, and surface properties, as these factors collectively influence how they interact with amyloidogenic proteins. Smaller NPs can infiltrate and break early-stage oligomers, whereas differences in shape influence binding efficiency and selectivity. Surface functionalization, such as hydrophobic modification, enhances the targeting of β -sheet-rich oligomers and helps to prevent further aggregation. The unique features of NPs make them promising candidates for inhibiting amyloid production in NDs. Shape and structure of nanoparticles play a crucial role in how they interact with amyloid oligomers, affecting their binding ability and preventing aggregation. Different nanoparticle geometries facilitate specific surface interactions that help to block oligomer formation and support structural stability. For example, Xiong et al. showed that peptide-functionalized AuNPs could effectively inhibit amyloid fibrillation. By attaching two peptide inhibitors (VVIA and LPFFD) to the surface of AuNPs using Au–S bonds, they created hybrid AuNPs that prevented oligomerization and reduced β -sheet formation, promoting random coil structures instead. The combined effect of these hybrid AuNPs was stronger than using the individual peptides alone, demonstrating the enhanced potential of nanoparticle-based treatments [93]. Building on these findings, Kim et al. showed that both the size and shape of AuNPs significantly affect A β aggregation. Their study revealed that smaller 20 nm AuNPs facilitated the formation of protofibrils and remained well-dispersed within A β aggregates, while larger 50 and 80 nm AuNPs promoted the formation of larger, plaque-like structures. This was due to increased A β accumulation on the

surface of the larger nanoparticles, which accelerated aggregation through localized concentration effects. Additionally, they examined the impact of nanoparticle shape and found that gold nanocubes led to larger A β aggregates compared to AuNRs, likely because of their greater surface area and more uniform structure. In contrast, spherical AuNPs disrupted β -sheet stacking, resulting in less stable aggregates. These findings emphasize that nanoparticle size and shape are key factors in controlling amyloid aggregation, providing valuable insights for designing nanoparticle-based therapies for AD [94]. Beyond size and shape, surface functionalization plays a crucial role in governing nanoparticle interactions with amyloidogenic proteins, influencing aggregation pathways and inhibition efficiency. Moore and colleagues investigated how 18 nm AuNPs with different surface coatings, viz., citrate, polyallylamine (PAH), and polyacrylic acid (PAA), affected the aggregation of A β 1–40 monomers. Their study found that PAA-coated nanoparticles completely inhibited aggregation, even at substoichiometric concentrations, while citrate- and PAH-coated nanoparticles reduced aggregation by 19% and 59%, respectively [95].

In contrast, John et al. used Thioflavin T fluorescence assays to explore the size-dependent effects of AuNPs on the fibrillogenesis of four peptides, namely, A β 40, NNFGAIL, GNNQQNY, and VQIYVK. Their results showed that 5 nm AuNPs effectively inhibited or delayed fibril formation in A β 40, GNNQQNY, and VQIYVK, but had no significant effect on NNFGAIL. In contrast, larger 20 nm AuNPs either accelerated fibril formation or had little impact on peptide aggregation [96]. In conclusion, these studies underscore the critical role of nanoparticle size, shape, and surface chemistry in modulating amyloid aggregation and inhibition. Smaller nanoparticles, particularly those around 5 nm in size, demonstrated superior inhibition by effectively interfering with early-stage oligomer formation. Additionally, surface functionalization significantly impacted aggregation dynamics, with different coatings (such as PAA, PAH, and citrate) showing different inhibitory effects. Structural variations, including the shape of nanoparticles, further influenced their ability to modulate amyloid fibrillogenesis. These findings highlight the importance of carefully designing nanoparticle-based strategies, considering size, shape, and surface modifications, to effectively inhibit oligomerization and provide potential therapeutic approaches for Alzheimer’s disease and other neurodegenerative conditions.

Distribution and clearance of NPs

Because of their small size and high surface area-to-volume ratio, NPs have the ability to cross biological barriers such as skin and BBB, which makes them valuable candidates for various biomedical applications such as diagnosis, therapeutics, and drug delivery. The efficacy of these NPs is closely linked to

their pharmacokinetic properties. The biodistribution, safety profile, and clearance mechanism of NPs plays a critical role in the clinical application of these NPs. Therefore, complete understanding of distribution and clearance of NPs *in vivo* is important. Following intravenous injection, NPs circulate through the bloodstream and are distributed to various organs and tissues (e.g., lungs, liver, kidney, and brain) based on their properties. Distribution is followed by their clearance, which mainly occurs through two pathways. The first pathway is the reticuloendothelial system (RES), and the second pathway is the renal and hepatic system [97,98]. The RES phagocytizes NPs and helps in their clearance. The renal and hepatic system eliminates NPs through kidneys and liver and excretion in urine and fecal matter, respectively. In the brain, the biodistribution of NP mainly occurs through the CSF. Direct infusion into the CSF results in rapid and widespread NP distribution, particularly in brainstem, cerebellum, and amygdala. The clearance of NPs from the brain is predominantly mediated by the paravascular glymphatic pathway, with studies suggesting that up to 80% of NPs are cleared through this route. Biodistribution and clearance of NPs have been shown to depend on their size and surface properties. Smaller graphene oxide (GO) sheets (20–70 nm) have been primarily distributed in kidney, spleen, and liver, while larger GO sheets (>200 nm) accumulate in the lungs [99]. For brain targeting, NPs between 100 and 300 nm have been found optimal for BBB transport, while those smaller than 15 nm show faster clearance. Surface characteristics also influence clearance; uncoated NPs have been rapidly cleared via the RES, whereas PEG-coated NPs exhibited extended circulation time and reduced RES clearance [99]. These findings highlight the importance of engineering nanoparticle size and surface properties to optimize therapeutic efficacy and clearance mechanisms. Achieving an ideal balance between prolonged circulation time, targeted delivery, and efficient clearance is crucial for maximizing the clinical potential of NPs.

Toxicity concerns of NPs and their implications on health

The prolonged retention and low clearance of NPs in the body may result in extended exposure, leading to their accumulation in various tissues and organs, such as liver, kidneys, brain, and lungs. This accumulation can cause both local and systemic toxicity. Additionally, NPs have the potential to trigger immune responses, including inflammation and allergic reactions, by activating macrophages and other immune cells [100]. The size and surface characteristics of NPs are critical in determining their interactions with cells, which may lead to oxidative stress, inflammation, and disruption of normal cellular processes. These effects can result in DNA damage, protein denaturation, and lipid peroxidation, potentially contributing to the development of chronic diseases [101]. The cumulative cellular damage

and inflammatory responses associated with NP exposure may give rise to long-term health complications. For instance, zinc oxide NPs have been shown to induce oxidative stress and DNA damage in mice models, along with alterations in various liver enzymes [102]. Similarly, SiO₂ NPs generated by Lin et al. caused toxicity in human bronchoalveolar cells through an increase in ROS levels. In addition to ROS, SiO₂ NPs also induce inflammation by upregulating inflammatory markers such as IL-1, IL-6, IL-8, and TNF- α , and causing mitochondrial damage [103]. NPs have the ability to cross the BBB and thus impact brain functions, which also makes them useful for treating neurodegenerative diseases. Upon crossing the BBB, NPs tend to accumulate in specific regions of the brain, where they can interact with neural cells, including neurons, astrocytes, and microglia. For example, iron oxide NPs can influence synaptic transmission, nerve conduction, neural inflammation, apoptosis, antioxidant responses, and immune cell infiltration [104]. Additionally, certain NPs, such as silver and copper oxide NPs, can disrupt the BBB, facilitating the entry of harmful substances into the brain, which may contribute to neurodegeneration [105]. The toxicological effects of NPs are further complicated by the fact that their long-term biological impacts are not fully understood. Given the complexity of their interactions with biological systems, NP behavior can vary based on factors such as size, shape, surface charge, and coating, making it challenging to predict potential health risks accurately. To mitigate these risks, surface modifications, such as coating NPs with biocompatible materials like polymers or lipids, can enhance their stability and prevent adverse cellular interactions. For instance, PEG modifications can help NPs evade the mononuclear phagocyte system, thus reducing toxicity [106]. Mesoporous SiO₂ nanoparticles (MSNs) with thiol surface modifications have been shown to reduce oxidative stress and cellular damage significantly compared to unmodified MSNs, thereby improving biocompatibility [107]. Furthermore, optimizing size and shape of NPs can further minimize harmful effects, and incorporating antioxidant and anti-inflammatory coatings can mitigate oxidative stress. For example, smaller NPs (<50 nm) with neutral or slightly negative surface charges diffuse more efficiently through brain white matter with reduced toxicity [108]. Targeted drug delivery systems can direct NPs to specific brain regions, reducing the risk of unintended exposure, while biodegradable NPs, such as those made from PLGA, degrade into non-toxic byproducts and reduce long-term accumulation in neural tissues [109]. Additionally, functionalizing NPs with specific ligands or receptor-targeting molecules, like polysorbate 80, can selectively target inflamed or diseased areas of the brain, minimizing off-target effects and systemic toxicity [110]. Additionally, promoting the clearance of NPs through the brain's waste removal systems, such as the glymphatic system, and developing NPs that mimic natural bio-

logical structures, could further improve safety and efficacy. These innovations provide a pathway for harnessing the potential of NPs in brain-targeted therapies, reducing toxicity, and maximizing therapeutic benefits. Therefore, while NPs hold significant promise for medical applications, their biological toxicity presents a considerable concern that necessitates rigorous regulation and continued scientific investigation.

Future perspectives


Current therapeutic approaches for AD have focused on developing clinical candidates that specifically target A β Os. Targeting A β Os has several advantages, primarily the early appearance of A β Os in AD patients, making them a critical focus for intervention. The foremost challenge is to create drug candidates with superior specificity and selectivity for A β Os alone. Additionally, it is essential to distinguish A β Os from other chemically similar and more abundant forms of the peptide, which complicates treatment strategies. Traditional methods for targeting A β Os, such as small-molecule inhibitors and passive immunization, have shown promise but often fall short in efficacy and specificity. Fortunately, NPs offer a promising solution for both the detection and disaggregation of A β Os and fibrils. Their unique characteristics, including small size, ease of surface modification, and multivalency effects, provide a potential pathway for therapeutic intervention in AD. These strategies can be categorized based on their composition and functionalization, enabling a diverse range of applications tailored to specific therapeutic needs. CNMs and metal-based

NPs have shown remarkable potential in detecting and inhibiting A β O aggregation, demonstrating their versatility in both research and clinical settings (Figure 6).

Moreover, biomimetic nanomaterials derived from cell primitives present an exciting frontier, leveraging natural biological processes for more effective targeting and treatment of A β Os. Nevertheless, challenges remain, including the need to evaluate the biocompatibility and toxicity of NPs and to develop scalable production processes.

Conclusion

The oligomer hypothesis has emerged as a leading explanation for the neurotoxicity observed in AD, highlighting A β Os as the major toxic species. A β Os are small, metastable aggregates with unique structural properties, including a higher β -sheet content, which complicates their targeting with conventional therapies. Their heterogeneity and transient nature present significant challenges in developing effective treatments. However, nanomaterial-based strategies offer a promising approach for detecting and inhibiting A β Os. Nanomaterials, because of their unique size and surface properties, provide several advantages, including the ability to cross the BBB, increased surface area for functionalization, and potential for high specificity in targeting A β Os. However, despite these promising attributes, significant challenges remain such as limited efficacy and specificity in targeting the diverse and dynamic forms of A β Os, as well as the potential for off-target effects. These limitations can



be overcome by optimizing the size, shape, and surface functionalization of NPs. Such efforts hold the potential to significantly improve the diagnosis, treatment, and management of AD, offering a transformative approach for addressing NDs.

Funding

The authors would like to thank CSIR-IHBT for infrastructural facilities. AA acknowledges the financial support from CSIR, India (MLP0201) and DBT (GAP0295). SR, TCS, MB, RB, and RD acknowledge UGC-SRF (191620021119), CSIR (JUN20C04388), DBT (DBT/2021-22/IHBT/1760), UGC-JRF (211610162757), and GAP0295 for their respective fellowships. The CSIR-IHBT communication number of this manuscript is 5691.

Conflict of Interest

The authors declare no competing financial interests.

Author Contributions

Shiwani Randhawa: conceptualization; formal analysis; investigation; visualization; writing – original draft; writing – review & editing. Trilok Chand Saini: conceptualization; data curation; investigation; validation; visualization; writing – review & editing. Manik Bathla: conceptualization; data curation; formal analysis; investigation; writing – review & editing. Rahul Bhardwaj: conceptualization; data curation; formal analysis; writing – review & editing. Rubina Dhiman: visualization; writing – original draft; writing – review & editing. Amitabha Acharya: conceptualization; formal analysis; funding acquisition; project administration; resources; supervision; validation; visualization; writing – original draft; writing – review & editing.

ORCID® iDs

Shiwani Randhawa - <https://orcid.org/0000-0001-7162-7490>

Trilok Chand Saini - <https://orcid.org/0000-0003-4722-6990>

Manik Bathla - <https://orcid.org/0000-0002-3029-2265>

Rahul Bhardwaj - <https://orcid.org/0009-0002-3768-4234>

Rubina Dhiman - <https://orcid.org/0009-0003-7018-2356>

Amitabha Acharya - <https://orcid.org/0000-0002-9013-9027>

Data Availability Statement

Data sharing is not applicable as no new data was generated or analyzed in this study.

References

- Cline, E. N.; Bicca, M. A.; Viola, K. L.; Klein, W. L. *J. Alzheimer's Dis.* **2018**, *64*, S567–S610. doi:10.3233/jad-179941
- Braak, H.; Braak, E. *Acta Neuropathol.* **1991**, *82*, 239–259. doi:10.1007/bf00308809
- Tomiya, T.; Shimada, H. *Int. J. Mol. Sci.* **2020**, *21*, 1413. doi:10.3390/ijms21041413
- Schöll, M.; Wall, A.; Thordardottir, S.; Ferreira, D.; Bogdanovic, N.; Långström, B.; Almkvist, O.; Graff, C.; Nordberg, A. *Neurology* **2012**, *79*, 229–236. doi:10.1212/wnl.0b013e31825fd1f8
- Tolar, M.; Hey, J.; Power, A.; Abushakra, S. *Int. J. Mol. Sci.* **2021**, *22*, 6355. doi:10.3390/ijms22126355
- Limegrover, C. S.; LeVine, H., III; Izzo, N. J.; Yurko, R.; Mozzoni, K.; Rehak, C.; Sadlek, K.; Safferstein, H.; Catalano, S. M. *J. Neurochem.* **2021**, *157*, 1316–1330. doi:10.1111/jnc.15212
- Yamazaki, Y.; Zhao, N.; Caulfield, T. R.; Liu, C.-C.; Bu, G. *Nat. Rev. Neurol.* **2019**, *15*, 501–518. doi:10.1038/s41582-019-0228-7
- Hashimoto, T.; Serrano-Pozo, A.; Hori, Y.; Adams, K. W.; Takeda, S.; Banerji, A. O.; Mitani, A.; Joyner, D.; Thyssen, D. H.; Bacskai, B. J.; Frosch, M. P.; Spire-Jones, T. L.; Finn, M. B.; Holtzman, D. M.; Hyman, B. T. *J. Neurosci.* **2012**, *32*, 15181–15192. doi:10.1523/jneurosci.1542-12.2012
- Randhawa, S.; Abidi, S. M. S.; Dar, A. I.; Acharya, A. *Int. J. Biol. Macromol.* **2021**, *193*, 1009–1020. doi:10.1016/j.ijbiomac.2021.10.195
- Muschol, M.; Hoyer, W. *Front. Mol. Biosci.* **2023**, *10*, 1120416. doi:10.3389/fmolb.2023.1120416
- Wang, Y.; Chen, J.; Gao, F.; Hu, M.; Wang, X. *Org. Biomol. Chem.* **2023**, *21*, 4540–4552. doi:10.1039/d3ob00509g
- Sevigny, J.; Chiao, P.; Bussière, T.; Weinreb, P. H.; Williams, L.; Maier, M.; Dunstan, R.; Salloway, S.; Chen, T.; Ling, Y.; O'Gorman, J.; Qian, F.; Arastu, M.; Li, M.; Chollate, S.; Brennan, M. S.; Quintero-Monzon, O.; Scannevin, R. H.; Arnold, H. M.; Engber, T.; Rhodes, K.; Ferrero, J.; Hang, Y.; Mikulskis, A.; Grimm, J.; Hock, C.; Nitsch, R. M.; Sandrock, A. *Nature* **2016**, *537*, 50–56. doi:10.1038/nature19323
- van Oostveen, W. M.; de Lange, E. C. M. *Int. J. Mol. Sci.* **2021**, *22*, 2110. doi:10.3390/ijms22042110
- Li, L.; He, R.; Yan, H.; Leng, Z.; Zhu, S.; Gu, Z. *Nano Today* **2022**, *47*, 101654. doi:10.1016/j.nantod.2022.101654
- Costa, R. O.; Lacor, P. N.; Ferreira, I. L.; Resende, R.; Auberson, Y. P.; Klein, W. L.; Oliveira, C. R.; Rego, A. C.; Pereira, C. M. F. *Aging Cell* **2012**, *11*, 823–833. doi:10.1111/j.1474-9726.2012.00848.x
- Texidó, L.; Martín-Satué, M.; Alberdi, E.; Solsona, C.; Matute, C. *Cell Calcium* **2011**, *49*, 184–190. doi:10.1016/j.ceca.2011.02.001
- Boland, K.; Flanagan, L.; Prehn, J. H. *Cell Death Dis.* **2013**, *4*, e725. doi:10.1038/cddis.2013.250
- Sharoar, M. G.; Palko, S.; Ge, Y.; Saido, T. C.; Yan, R. *Mol. Neurodegener.* **2021**, *16*, 45. doi:10.1186/s13024-021-00464-1
- Viola, K. L.; Klein, W. L. *Acta Neuropathol.* **2015**, *129*, 183–206. doi:10.1007/s00401-015-1386-3
- Kim, K. S.; Miller, D. L.; Sapienza, V. J.; Chen, C. M. J.; Bai, C.; Grundke-Iqbal, I.; Wisniewski, H. M. *Neurosci. Res. Commun.* **1998**, *2*, 121–130.
- Kim, K. S.; Wen, G. Y.; Bancher, C.; Chen, C. M. J.; Sapienza, V. J.; Hong, H.; Wisniewski, H. M. *Neurosci. Res. Commun.* **1990**, *7*, 113–122.
- Kayed, R.; Head, E.; Thompson, J. L.; McIntire, T. M.; Milton, S. C.; Cotman, C. W.; Glabe, C. G. *Science* **2003**, *300*, 486–489. doi:10.1126/science.1079469
- Kayed, R.; Head, E.; Sarsoza, F.; Saing, T.; Cotman, C. W.; Necula, M.; Margol, L.; Wu, J.; Breydo, L.; Thompson, J. L.; Rasool, S.; Gurlo, T.; Butler, P.; Glabe, C. G. *Mol. Neurodegener.* **2007**, *2*, 18. doi:10.1186/1750-1326-2-18

24. Kayed, R.; Canto, I.; Breydo, L.; Rasool, S.; Lukacsovich, T.; Wu, J.; Albay, R., III; Pensalfini, A.; Yeung, S.; Head, E.; Marsh, J. L.; Glabe, C. *Mol. Neurodegener.* **2010**, *5*, 57. doi:10.1186/1750-1326-5-57
25. Lacor, P. N.; Buniel, M. C.; Chang, L.; Fernandez, S. J.; Gong, Y.; Viola, K. L.; Lambert, M. P.; Velasco, P. T.; Bigio, E. H.; Finch, C. E.; Krafft, G. A.; Klein, W. L. *J. Neurosci.* **2004**, *24*, 10191–10200. doi:10.1523/jneurosci.3432-04.2004
26. Englund, H.; Sehlin, D.; Johansson, A.-S.; Nilsson, L. N. G.; Gellerfors, P.; Paulie, S.; Lannfelt, L.; Pettersson, F. E. *J. Neurochem.* **2007**, *103*, 334–345. doi:10.1111/j.1471-4159.2007.04759.x
27. Magnusson, K.; Sehlin, D.; Syvänen, S.; Svedberg, M. M.; Philipson, O.; Söderberg, L.; Tegerstedt, K.; Holmquist, M.; Gellerfors, P.; Tolmachev, V.; Antoni, G.; Lannfelt, L.; Hall, H.; Nilsson, L. N. G. *J. Alzheimer's Dis.* **2013**, *37*, 29–40. doi:10.3233/jad-130029
28. Sehlin, D.; Hedlund, M.; Lord, A.; Englund, H.; Gellerfors, P.; Paulie, S.; Lannfelt, L.; Pettersson, F. E. *Neurodegener. Dis.* **2011**, *8*, 117–123. doi:10.1159/000316530
29. Haynes, J. R.; Whitmore, C. A.; Behof, W. J.; Landman, C. A.; Ong, H. H.; Feld, A. P.; Suero, I. C.; Greer, C. B.; Gore, J. C.; Wijesinghe, P.; Matsubara, J. A.; Wadzinski, B. E.; Spiller, B. W.; Pham, W. *Sci. Rep.* **2024**, *14*, 16086. doi:10.1038/s41598-024-66970-6
30. Linse, S.; Scheidt, T.; Bernfur, K.; Vendruscolo, M.; Dobson, C. M.; Cohen, S. I. A.; Sileikis, E.; Lundqvist, M.; Qian, F.; O'Malley, T.; Bussiére, T.; Weinreb, P. H.; Xu, C. K.; Meisl, G.; Devenish, S. R. A.; Knowles, T. P. J.; Hansson, O. *Nat. Struct. Mol. Biol.* **2020**, *27*, 1125–1133. doi:10.1038/s41594-020-0505-6
31. Cummings, J. L.; Cohen, S.; Van Dyck, C. H.; Brody, M.; Curtis, C.; Cho, W.; Ward, M.; Friesenhahn, M.; Rabe, C.; Brunstein, F.; Quartino, A.; Honigberg, L. A.; Fujii, R. N.; Clayton, D.; Mortensen, D.; Ho, C.; Paul, R. *Neurology* **2018**, *90*, e1889–e1897. doi:10.1212/wnl.0000000000005550
32. Tolar, M.; Abushakra, S.; Hey, J. A.; Porsteinsson, A.; Sabbagh, M. *Alzheimer's Res. Ther.* **2020**, *12*, 95. doi:10.1186/s13195-020-00663-w
33. Salloway, S.; Sperling, R.; Fox, N. C.; Blennow, K.; Klunk, W.; Raskind, M.; Sabbagh, M.; Honig, L. S.; Porsteinsson, A. P.; Ferris, S.; Reichert, M.; Ketter, N.; Nejadnik, B.; Guenzler, V.; Miloslavsky, M.; Wang, D.; Lu, Y.; Lull, J.; Tudor, I. C.; Liu, E.; Grundman, M.; Yuen, E.; Black, R.; Brashear, H. R. *N. Engl. J. Med.* **2014**, *370*, 322–333. doi:10.1056/nejmoa1304839
34. Gibbs, E.; Silverman, J. M.; Zhao, B.; Peng, X.; Wang, J.; Wellington, C. L.; Mackenzie, I. R.; Plotkin, S. S.; Kaplan, J. M.; Cashman, N. R. *Sci. Rep.* **2019**, *9*, 9870. doi:10.1038/s41598-019-46306-5
35. Yang, F.; Lim, G. P.; Begum, A. N.; Ubeda, O. J.; Simmons, M. R.; Ambegaokar, S. S.; Chen, P. P.; Kaye, R.; Glabe, C. G.; Frautschi, S. A.; Cole, G. M. *J. Biol. Chem.* **2005**, *280*, 5892–5901. doi:10.1074/jbc.m404751200
36. Acharya, A.; Stockmann, J.; Beyer, L.; Rudack, T.; Nabers, A.; Gumbart, J. C.; Gerwert, K.; Batista, V. S. *Biophys. J.* **2020**, *119*, 349–359. doi:10.1016/j.bpj.2020.05.033
37. Zhang, S.; Wang, P.; Ren, L.; Hu, C.; Bi, J. *Alzheimer's Res. Ther.* **2016**, *8*, 40. doi:10.1186/s13195-016-0206-x
38. Limbicker, R.; Chia, S.; Ruggeri, F. S.; Perni, M.; Cascella, R.; Heller, G. T.; Meisl, G.; Mannini, B.; Habchi, J.; Michaels, T. C. T.; Challa, P. K.; Ahn, M.; Casford, S. T.; Fernando, N.; Xu, C. K.; Kloss, N. D.; Cohen, S. I. A.; Kumita, J. R.; Cecchi, C.; Zasloff, M.; Linse, S.; Knowles, T. P. J.; Chiti, F.; Vendruscolo, M.; Dobson, C. M. *Nat. Commun.* **2019**, *10*, 225. doi:10.1038/s41467-018-07699-5
39. Necula, M.; Breydo, L.; Milton, S.; Kaye, R.; van der Veer, W. E.; Tone, P.; Glabe, C. G. *Biochemistry* **2007**, *46*, 8850–8860. doi:10.1021/bi700411k
40. Hou, T.-T.; Yang, H.-Y.; Wang, W.; Wu, Q.-Q.; Tian, Y.-R.; Jia, J.-P. *J. Alzheimer's Dis.* **2018**, *62*, 1803–1813. doi:10.3233/jad-171110
41. Li, X.; Zhang, X.; Ladiwala, A. R. A.; Du, D.; Yadav, J. K.; Tessier, P. M.; Wright, P. E.; Kelly, J. W.; Buxbaum, J. N. *J. Neurosci.* **2013**, *33*, 19423–19433. doi:10.1523/jneurosci.2561-13.2013
42. Taylor, M.; Moore, S.; Mayes, J.; Parkin, E.; Beeg, M.; Canovi, M.; Gobbi, M.; Mann, D. M. A.; Allsop, D. *Biochemistry* **2010**, *49*, 3261–3272. doi:10.1021/bi100144m
43. Wood, S. J.; Wetzel, R.; Martin, J. D.; Hurle, M. R. *Biochemistry* **1995**, *34*, 724–730. doi:10.1021/bi00003a003
44. Klein, A. N.; Ziehm, T.; Tusche, M.; Buitenhuis, J.; Bartnik, D.; Boeddrich, A.; Wiglenda, T.; Wanker, E.; Funke, S. A.; Brenner, O.; Gremer, L.; Kutzsche, J.; Willbold, D. *PLoS One* **2016**, *11*, e0153035. doi:10.1371/journal.pone.0153035
45. Lacham-Hartman, S.; Moshe, R.; Ben-Zichri, S.; Shmidov, Y.; Bitton, R.; Jelinek, R.; Papo, N. *ACS Chem. Neurosci.* **2023**, *14*, 3385–3397. doi:10.1021/acschemneuro.3c00208
46. Willander, H.; Presto, J.; Askarieh, G.; Biverstål, H.; Frohm, B.; Knight, S. D.; Johansson, J.; Linse, S. *J. Biol. Chem.* **2012**, *287*, 31608–31617. doi:10.1074/jbc.m112.393157
47. Arimon, M.; Grimminger, V.; Sanz, F.; Lashuel, H. A. *J. Mol. Biol.* **2008**, *384*, 1157–1173. doi:10.1016/j.jmb.2008.09.063
48. Sun, Y.; Ding, F. *J. Phys. Chem. B* **2020**, *124*, 10138–10146. doi:10.1021/acs.jpcc.0c07256
49. Zhao, Z.; Liu, Y.; Ruan, S.; Hu, Y. *Int. J. Nanomed.* **2023**, *18*, 7825–7845. doi:10.2147/ijn.s444115
50. Sandberg, A.; Berenjeno-Correa, E.; Rodriguez, R. C.; Axenhus, M.; Weiss, S. S.; Batenburg, K.; Hoozemans, J. J. M.; Tjernberg, L. O.; Scheper, W. *Alzheimer's Res. Ther.* **2022**, *14*, 196. doi:10.1186/s13195-022-01141-1
51. Viola, K. L.; Sbarboro, J.; Sureka, R.; De, M.; Bicca, M. A.; Wang, J.; Vasavada, S.; Satpathy, S.; Wu, S.; Joshi, H.; Velasco, P. T.; MacRena, K.; Waters, E. A.; Lu, C.; Phan, J.; Lacor, P.; Prasad, P.; David, V. P.; Klein, W. L. *Nat. Nanotechnol.* **2015**, *10*, 91–98. doi:10.1038/nnano.2014.254
52. Wang, C.; Wang, X.; Chan, H.-N.; Liu, G.; Wang, Z.; Li, H.-W.; Wong, M. S. *Adv. Funct. Mater.* **2020**, *30*, 1909529. doi:10.1002/adfm.201909529
53. Sun, L.; Zhong, Y.; Gui, J.; Wang, X.; Zhuang, X.; Weng, J. *Int. J. Nanomed.* **2018**, *13*, 843–856. doi:10.2147/ijn.s152163
54. Yu, S.; Li, T.; Ji, F.; Zhao, S.; Liu, K.; Zhang, Z.; Zhang, W.; Mei, Y. *Mater. Today Adv.* **2022**, *14*, 100231. doi:10.1016/j.mta.2022.100231
55. Elbassal, E. A.; Morris, C.; Kent, T. W.; Lantz, R.; Ojha, B.; Wojcikiewicz, E. P.; Du, D. *J. Phys. Chem. C* **2017**, *121*, 20007–20015. doi:10.1021/acs.jpcc.7b05169
56. Liu, L.; Chang, Y.; Yu, J.; Jiang, M.; Xia, N. *Sens. Actuators, B* **2017**, *251*, 359–365. doi:10.1016/j.snb.2017.05.106
57. Liu, X.-g.; Zhang, L.; Lu, S.; Liu, D.-q.; Huang, Y.-r.; Zhu, J.; Zhou, W.-w.; Yu, X.-l.; Liu, R.-t. *J. Nanobiotechnol.* **2020**, *18*, 160. doi:10.1186/s12951-020-00723-1

58. Liu, X.-G.; Zhang, L.; Lu, S.; Liu, D.-Q.; Zhang, L.-X.; Yu, X.-L.; Liu, R.-T. *Int. J. Nanomed.* **2020**, *15*, 4919–4932. doi:10.2147/ijn.s240953
59. Brambilla, D.; Verpillot, R.; Le Droumaguet, B.; Nicolas, J.; Taverna, M.; Kóña, J.; Lettierio, B.; Hashemi, S. H.; De Kimpe, L.; Canovi, M.; Gobbi, M.; Nicolas, V.; Scheper, W.; Moghimi, S. M.; Tvaroška, I.; Couvreur, P.; Andrieux, K. *ACS Nano* **2012**, *6*, 5897–5908. doi:10.1021/nn300489k
60. Parikh, A.; Kathawala, K.; Li, J.; Chen, C.; Shan, Z.; Cao, X.; Zhou, X.-F.; Garg, S. *Drug Delivery Transl. Res.* **2018**, *8*, 1406–1420. doi:10.1007/s13346-018-0570-0
61. Javed, I.; Peng, G.; Xing, Y.; Yu, T.; Zhao, M.; Kakinen, A.; Faridi, A.; Parish, C. L.; Ding, F.; Davis, T. P.; Ke, P. C.; Lin, S. *Nat. Commun.* **2019**, *10*, 3780. doi:10.1038/s41467-019-11762-0
62. Xie, L.; Lin, D.; Luo, Y.; Li, H.; Yang, X.; Wei, G. *Biophys. J.* **2014**, *107*, 1930–1938. doi:10.1016/j.bpj.2014.08.034
63. Paul, P. S.; Cho, J.-Y.; Wu, Q.; Karthivashan, G.; Grabovac, E.; Wille, H.; Kulka, M.; Kar, S. *J. Nanobiotechnol.* **2022**, *20*, 67. doi:10.1186/s12951-022-01269-0
64. Lee, J.-H.; Kang, D.-Y.; Lee, T.; Kim, S.-U.; Oh, B.-K.; Choi, J.-W. *J. Nanosci. Nanotechnol.* **2009**, *9*, 7155–7160. doi:10.1166/jnn.2009.1613
65. Kuo, Y.-C.; Tsai, H.-C. *Mater. Sci. Eng., C* **2018**, *91*, 445–457. doi:10.1016/j.msec.2018.05.062
66. Li, N.; Shu, J.; Yang, X.; Wei, W.; Yan, A. *Front. Cell. Neurosci.* **2022**, *16*, 874102. doi:10.3389/fncel.2022.874102
67. Hou, K.; Zhao, J.; Wang, H.; Li, B.; Li, K.; Shi, X.; Wan, K.; Ai, J.; Lv, J.; Wang, D.; Huang, Q.; Wang, H.; Cao, Q.; Liu, S.; Tang, Z. *Nat. Commun.* **2020**, *11*, 4790. doi:10.1038/s41467-020-18525-2
68. Randhawa, S.; Dar, A. I.; Saini, T. C.; Bathla, M.; Acharya, A. *Nano Today* **2024**, *56*, 102243. doi:10.1016/j.nantod.2024.102243
69. Jin, L.; Wang, Q.; Yang, M.; Zhang, J.; Liang, H.; Tan, H.; Liang, Z.; Ma, X.; Liu, J.; Li, H.; Cai, X.; Cui, W.; Zhao, L. *Med. Novel Technol. Devices* **2022**, *15*, 100150. doi:10.1016/j.medntd.2022.100150
70. Xie, L.; Luo, Y.; Lin, D.; Xi, W.; Yang, X.; Wei, G. *Nanoscale* **2014**, *6*, 9752–9762. doi:10.1039/c4nr01005a
71. Lei, J.; Qi, R.; Xie, L.; Xi, W.; Wei, G. *RSC Adv.* **2017**, *7*, 13947–13956. doi:10.1039/c6ra27608c
72. Li, H.; Luo, Y.; Derreumaux, P.; Wei, G. *Biophys. J.* **2011**, *101*, 2267–2276. doi:10.1016/j.bpj.2011.09.046
73. Lin, D.; Qi, R.; Li, S.; He, R.; Li, P.; Wei, G.; Yang, X. *ACS Chem. Neurosci.* **2016**, *7*, 1232–1240. doi:10.1021/acscchemneuro.6b00101
74. Voronova, A.; Barras, A.; Plaisance, V.; Pawlowski, V.; Boukherroub, R.; Abderrahmani, A.; Szunerits, S. *Nanoscale* **2022**, *14*, 14683–14694. doi:10.1039/d2nr03173f
75. Zhou, Y.; Li, C.; Li, X.; Zhu, X.; Ye, B.; Xu, M. *Anal. Methods* **2018**, *10*, 4430–4437. doi:10.1039/c8ay00736e
76. Phan, L.-M.-T.; Cho, S. *Biomolecules* **2021**, *11*, 948. doi:10.3390/biom11070948
77. Zhao, C.; Wang, A.; Tang, X.; Qin, J. *Mater. Today Adv.* **2022**, *14*, 100250. doi:10.1016/j.mtadv.2022.100250
78. Gallo-Orive, Á.; Moreno-Guzmán, M.; Sanchez-Paniagua, M.; Montero-Calle, A.; Barderas, R.; Escarpa, A. *Anal. Chem. (Washington, DC, U. S.)* **2024**, *96*, 5509–5518. doi:10.1021/acs.analchem.3c05665
79. Saini, R.; Navale, G. R.; Singh, S.; Singh, H. K.; Chauhan, R.; Agrawal, S.; Sarkar, D.; Sarma, M.; Ghosh, K. *Int. J. Biol. Macromol.* **2023**, *248*, 125847. doi:10.1016/j.ijbiomac.2023.125847
80. Cabaleiro-Lago, C.; Quinlan-Pluck, F.; Lynch, I.; Lindman, S.; Minogue, A. M.; Thulin, E.; Walsh, D. M.; Dawson, K. A.; Linse, S. *J. Am. Chem. Soc.* **2008**, *130*, 15437–15443. doi:10.1021/ja8041806
81. Sardar Sinha, M.; Ansell-Schultz, A.; Civitelli, L.; Hildesjö, C.; Larsson, M.; Lannfelt, L.; Ingelsson, M.; Hallbeck, M. *Acta Neuropathol.* **2018**, *136*, 41–56. doi:10.1007/s00401-018-1868-1
82. Gallart-Palau, X.; Guo, X.; Serra, A.; Sze, S. K. *Alzheimer's Res. Ther.* **2020**, *12*, 54. doi:10.1186/s13195-020-00623-4
83. Soliman, H. M.; Ghonaim, G. A.; Gharib, S. M.; Chopra, H.; Farag, A. K.; Hassanin, M. H.; Nagah, A.; Emad-Eldin, M.; Hashem, N. E.; Yahya, G.; Emam, S. E.; Hassan, A. E. A.; Attia, M. S. *Int. J. Mol. Sci.* **2021**, *22*, 10794. doi:10.3390/ijms221910794
84. Bodart-Santos, V.; de Carvalho, L. R. P.; de Godoy, M. A.; Batista, A. F.; Saraiva, L. M.; Lima, L. G.; Abreu, C. A.; De Felice, F. G.; Galina, A.; Mendez-Otero, R.; Ferreira, S. T. *Stem Cell Res. Ther.* **2019**, *10*, 332. doi:10.1186/s13287-019-1432-5
85. Deng, Z.; Wang, J.; Xiao, Y.; Li, F.; Niu, L.; Liu, X.; Meng, L.; Zheng, H. *Theranostics* **2021**, *11*, 4351–4362. doi:10.7150/thno.52436
86. Yuyama, K.; Sun, H.; Mitsutake, S.; Igarashi, Y. *J. Biol. Chem.* **2012**, *287*, 10977–10989. doi:10.1074/jbc.m111.324616
87. Senapati, S.; Tripathi, K.; Awad, K.; Rahimpour, S. *Small* **2024**, *20*, 2311670. doi:10.1002/smll.202311670
88. Chang, L.; Bakhos, L.; Wang, Z.; Venton, D. L.; Klein, W. L. *J. Mol. Neurosci.* **2003**, *20*, 305–314. doi:10.1385/jmn:20:3:305
89. Zhou, Y.; Zhang, H.; Liu, L.; Li, C.; Chang, Z.; Zhu, X.; Ye, B.; Xu, M. *Sci. Rep.* **2016**, *6*, 35186. doi:10.1038/srep35186
90. Vandenberghe, R.; Riviere, M.-E.; Caputo, A.; Sovago, J.; Maguire, R. P.; Farlow, M.; Marotta, G.; Sanchez-Valle, R.; Scheltens, P.; Ryan, J. M.; Graf, A. *Alzheimer's Dementia* **2017**, *3*, 10–22. doi:10.1016/j.trci.2016.12.003
91. Nizami, S.; Hall-Roberts, H.; Warriar, S.; Cowley, S. A.; Di Daniel, E. *Br. J. Pharmacol.* **2019**, *176*, 3515–3532. doi:10.1111/bph.14618
92. Carradori, D.; Balducci, C.; Re, F.; Brambilla, D.; Le Droumaguet, B.; Flores, O.; Gaudin, A.; Mura, S.; Forloni, G.; Ordoñez-Gutiérrez, L.; Wandosell, F.; Masserini, M.; Couvreur, P.; Nicolas, J.; Andrieux, K. *Nanomedicine (N. Y., NY, U. S.)* **2018**, *14*, 609–618. doi:10.1016/j.nano.2017.12.006
93. Xiong, N.; Zhao, Y.; Dong, X.; Zheng, J.; Sun, Y. *Small* **2017**, *13*, 1601666. doi:10.1002/smll.201601666
94. Kim, Y.; Park, J.-H.; Lee, H.; Nam, J.-M. *Sci. Rep.* **2016**, *6*, 19548. doi:10.1038/srep19548
95. Moore, K. A.; Pate, K. M.; Soto-Ortega, D. D.; Lohse, S.; van der Munnik, N.; Lim, M.; Jackson, K. S.; Lyles, V. D.; Jones, L.; Glasgow, N.; Napumeheno, V. M.; Mobley, S.; Uline, M. J.; Mahtab, R.; Murphy, C. J.; Moss, M. A. *J. Biol. Eng.* **2017**, *11*, 5. doi:10.1186/s13036-017-0047-6
96. John, T.; Adler, J.; Elsner, C.; Petzold, J.; Krueger, M.; Martin, L. L.; Huster, D.; Risselada, H. J.; Abel, B. *J. Colloid Interface Sci.* **2022**, *622*, 804–818. doi:10.1016/j.jcis.2022.04.134
97. von Roemeling, C.; Jiang, W.; Chan, C. K.; Weissman, I. L.; Kim, B. Y. S. *Trends Biotechnol.* **2017**, *35*, 159–171. doi:10.1016/j.tibtech.2016.07.006
98. Wei, Y.; Quan, L.; Zhou, C.; Zhan, Q. *Nanomedicine (London, U. K.)* **2018**, *13*, 1495–1512. doi:10.2217/nnm-2018-0040
99. Kumar, M.; Kulkarni, P.; Liu, S.; Chemuturi, N.; Shah, D. K. *Adv. Drug Delivery Rev.* **2023**, *194*, 114708. doi:10.1016/j.addr.2023.114708
100. Ramakrishna, D.; Rao, P. *eJIFCC* **2011**, *22*, 92–101.

101. Donaldson, K.; Tran, L.; Jimenez, L. A.; Duffin, R.; Newby, D. E.; Mills, N.; MacNee, W.; Stone, V. *Part. Fibre Toxicol.* **2005**, *2*, 10. doi:10.1186/1743-8977-2-10
102. Sharma, V.; Singh, P.; Pandey, A. K.; Dhawan, A. *Mutat. Res., Genet. Toxicol. Environ. Mutagen.* **2012**, *745*, 84–91. doi:10.1016/j.mrgentox.2011.12.009
103. Lin, W.; Huang, Y.-w.; Zhou, X.-D.; Ma, Y. *Toxicol. Appl. Pharmacol.* **2006**, *217*, 252–259. doi:10.1016/j.taap.2006.10.004
104. Teleanu, D. M.; Chircov, C.; Grumezescu, A. M.; Volceanov, A.; Teleanu, R. I. *J. Clin. Med.* **2018**, *7*, 490. doi:10.3390/jcm7120490
105. Jiang, X.; Gao, H., Eds. *Neurotoxicity of Nanomaterials and Nanomedicine*; Academic Press, 2016.
106. Zia, S.; Islam Aqib, A.; Muneer, A.; Fatima, M.; Atta, K.; Kausar, T.; Zaheer, C.-N. F.; Ahmad, I.; Saeed, M.; Shafique, A. *Front. Neurosci.* **2023**, *17*, 1127460. doi:10.3389/fnins.2023.1127460
107. Zhou, M.; Xie, L.; Fang, C.-J.; Yang, H.; Wang, Y.-J.; Zhen, X.-Y.; Yan, C.-H.; Wang, Y.; Zhao, M.; Peng, S. *RSC Adv.* **2016**, *6*, 2800–2809. doi:10.1039/c5ra17517h
108. Yuan, T.; Gao, L.; Zhan, W.; Dini, D. *Pharm. Res.* **2022**, *39*, 767–781. doi:10.1007/s11095-022-03222-0
109. Wiwatchaitawee, K.; Ebeid, K.; Quarterman, J. C.; Naguib, Y.; Ali, M. Y.; Oliva, C.; Griguer, C.; Salem, A. K. *Bioconjugate Chem.* **2022**, *33*, 1957–1972. doi:10.1021/acs.bioconjchem.1c00479
110. Pinheiro, R. G. R.; Coutinho, A. J.; Pinheiro, M.; Neves, A. R. *Int. J. Mol. Sci.* **2021**, *22*, 11654. doi:10.3390/ijms222111654

License and Terms

This is an open access article licensed under the terms of the Beilstein-Institut Open Access License Agreement (<https://www.beilstein-journals.org/bjnano/terms>), which is identical to the Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0>). The reuse of material under this license requires that the author(s), source and license are credited. Third-party material in this article could be subject to other licenses (typically indicated in the credit line), and in this case, users are required to obtain permission from the license holder to reuse the material.

The definitive version of this article is the electronic one which can be found at:
<https://doi.org/10.3762/bjnano.16.44>